Results 101 to 110 of about 49,464 (141)

Insights on postneoadjuvant treatment among patients with triple-negative breast cancer and residual disease after neoadjuvant therapy: can expert consensus help to interpret the current evidence? [PDF]

Br J Cancer
Valachis A, Geisler J, Karihtala P, Tuxen MK.   +3 more
europepmc   +1 more source

Cost-effectiveness analysis of pembrolizumab plus trastuzumab and chemotherapy as first-line treatment for HER2-positive gastric or gastroesophageal junction adenocarcinoma. [PDF]

Front Med (Lausanne)
Yang H, Ge W, Jiang S, Lan X, Du X.
europepmc   +1 more source

Capecitabine-based triplet (TPX) as induction chemotherapy in advanced head and neck cancer: a daycare-based cohort study. [PDF]

Ecancermedicalscience
Biswas R, Choudhury KB, Halder A.
europepmc   +1 more source

Refractory Esophageal Varices Requiring Transjugular Intrahepatic Portosystemic Shunt Placement in Oxaliplatin-Induced Portosinusoidal Vascular Disorder. [PDF]

ACG Case Rep J
Vu J, Aggarwal A, Morshedi M, Medici V.
europepmc   +1 more source

A case of invasive lobular carcinoma with signet-ring-cell differentiation treated with multidisciplinary therapy: a rare case report. [PDF]

Front Oncol
Takuwa H, Hori T, Goda N, Takeuchi M.
europepmc   +1 more source

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501). [PDF]

Int J Cancer
Akkus E, Kayaalp M, Ergözoğlu MA, Koç Kuş I, Bayram D, Kılıçtaş B, Ayvaz Güneyin E, Kalem A, Temizyürek H, Çatlı MM, Akarca MS, Mıldanoğlu MM, Turhan G, Kara M, Arak H, Arslan Tan F, Paçacı B, Yeşilyurt B, Akdoğan O, Çetin EB, Çelik S, Keskin Uzundere F, Şahin E, Sadak Öcal Z, Şeker Can L, Köylü B, Fidan MC, Kaplan Tüzün E, Şakalar T, Sertesen Çamöz E, Yüksel HÇ, Balçık OY, Peker P, Yılmaz M, Ala Enli Ş, Kölemen E, Oyucu Orhan S, Düzköprü Y, Ersoy M, Akın Telli T, Yılmaz M, İlhan Y, Yıldırım A, Coşar R, Ürün M, Önder AH, Araz M, Bayram E, Yeşil Çınkır H, Alkan A, Gürbüz M, Avcı N, Paksoy Türköz F, Kara İO, Köse F, Ünek İT, Bilici A, Bal Ö, Yalçın Ş, Rimassa L, Yaşar HA.   +60 more
europepmc   +1 more source

Maintenance capecitabine after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma: final analysis from the PLATFORM trial. [PDF]

Br J Cancer
Gordon A, Tran A, Fong C, Cromarty S, Piadel K, Zhitkov O, Leamon B, Cafferkey C, Davidson M, Das P, Petty R, Roques T, Hewish M, Morgan C, Waddell T, Darby S, Bradshaw A, Rao S, Starling N, Chau I, Cunningham D.   +20 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Capecitabine

Drugs, 1999
Capecitabine is an orally administered fluoropyrimidine carbamate used for the treatment of paclitaxel- or anthracycline-refractory breast cancer. Capecitabine is metabolised via a 3-step process to the active agent fluorouracil. The final step of this process occurs preferentially in malignant tissue.
M, Dooley, K L, Goa
openaire   +2 more sources